They can recommend the safest way to do so, which may include a gradual taper over the course of several weeks to minimize hunger spikes and weight regain
In the SURMOUNT5 trial, participants lost an average of 20.2 % of their baseline body weight over 72 weeks with tirzepatide, with a greater proportion achieving weight-loss thresholds of 1525 % compared with semaglutide
Lower doses produced more modest reductions: 4 mg dose: approximately 8.7% mean weight reduction 0.5 mg dose: approximately 2.0% mean weight reduction Placebo: a small mean weight gain of approximately 2.0% Readers should note that these figures are drawn from a single phase 2 trial with a relatively small sample size and 24-week duration
Nausea, vomiting, diarrhea, stomach pain, and constipation, especially in the first weeks as your body adjusts
Wegovy (2021) received priority review six months because effective obesity medications were limited at the time